Evolving paradigms in the medical treatment of glaucoma

International Ophthalmology

Volumn 25, Issue 5-6, 2004, Pages 253-265

  Cohen, John S ^a   Khatana, Anup K ^a   Greff, Linda J ^a  

^a CINCINNATI EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; CALCIUM ANTAGONIST; CARBONATE DEHYDRATASE INHIBITOR; CARTEOLOL; CATECHOLAMINE DERIVATIVE; CHOLINERGIC RECEPTOR STIMULATING AGENT; DIGITALIS; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; ENDOTHELIN 1; LATANOPROST; LEVOBUNOLOL; METIPRANOLOL; PROSTAGLANDIN DERIVATIVE; PURITE; QUINIDINE; TIMOLOL; TRAVOPROST; UNOPROSTONE ISOPROPYL ESTER;

AIRWAY OBSTRUCTION; ALLERGIC CONJUNCTIVITIS; AMNESIA; ANTIHYPERTENSIVE ACTIVITY; AQUEOUS HUMOR FORMATION; ARTICLE; BINDING AFFINITY; BRADYCARDIA; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONJUNCTIVAL HYPEREMIA; DEPRESSION; DISEASE COURSE; DISEASE EXACERBATION; DRUG ANTAGONISM; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; EYE ALLERGY; EYE BLOOD FLOW; EYE IRRITATION; FATIGUE; GLAUCOMA; HEART ARRHYTHMIA; HERPES SIMPLEX KERATITIS; HUMAN; HYPERPIGMENTATION; HYPERTRICHOSIS; IMPOTENCE; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; IRIS DISEASE; LIBIDO DISORDER; MEDICAL DECISION MAKING; MONOTHERAPY; NEUROPROTECTION; NONHUMAN; PUNCTATE KERATITIS; RETINA MACULA CYSTOID EDEMA; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT RESPONSE; WEAKNESS;

EID: 33644889928     PISSN: 01655701     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10792-005-7581-9     Document Type: Article

References (94)

1. HD Jampel 1997 Target pressure in glaucoma therapy J Glaucoma 6 133-138 1:STN:280:ByiB2Mzjsl0%3D 9098822
2. Traverso CE. Case discussion: Target IOP in glaucoma management. Syllabus. Glaucoma 1999: Concepts and Controversies. Glaucoma Subspecialty Day, American Academy of Ophthalmology, pp. 33-36.
3. T Realini RD Fechtner 2000 Target intraocular pressure in glaucoma management Ophthalmol Clin North Am 13 407-415 10.1016/ S0896-1549(05)70202-9
4. K Singh G Spaeth T Zimmerman D Minckler 2000 Target pressureglaucomatologists' holey grail Ophthalmology 107 629-630 1:STN:280:DC%2BD3c3ivVyisg%3D%3D 10768323
5. The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429-440.
6. LK Mao WC Stewart MB Shields 1991 Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma Am J Ophthalmol 111 51-55 1:STN:280:By6D1M%2FhvVM%3D 1985490
7. R Vogel RP Crick RB Newson M Shipley H Blackmore CJ Bulpitt 1990 Association between intraocular pressure and loss of visual field in chronic simple glaucoma Br J Ophthalmol 74 3-6 1:STN:280:By%2BC28jgsFE%3D 2306441
8. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998; 126: 487-497.
9. MJ Cartwright DR Anderson 1988 Correlation of asymmetric damage with asymmetric intraocular pressure in normal-tension glaucoma (low-tension glaucoma) Arch Ophthalmol 106 898-900 1:STN:280:BieB28fltVE%3D 3390051
10. Heijl A, Leske C, Bengtsson B, Hyman L, Bengtsson B, Hussein M, and the Early Manifest Glaucoma Trial. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268-1279.
11. Preferred practice pattern, primary open-angle glaucoma, San Francisco, CA: American Academy of Ophthalmology.
12. MA Kass DK Heuer EJ Higginbotham 2002 The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma Arch Ophthalmol 120 701-713 12049574
13. P Palmberg 2002 Answers from the ocular hypertension treatment study Arch Ophthalmol 120 829-830 12049591
14. S Asrani R Zeimer J Wilensky D Gieser S Vitale K Lindenmuth 2000 Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma J Glaucoma 9 134-142 1:STN:280:DC%2BD3c3kt1OitA%3D%3D 10782622
15. RF Brubaker 2001 Mechanism of action of bimatoprost (Lumigan) Surv Ophthalmol 45 suppl 4 S347-S351 11434937
16. M DeSaint Jean P Brignole AF Bringuier 1999 Effects of benzalkonium chloride on growth and survival of Change conjunctival cells Invest Ophthalmol Vis Sci 40 619-630 1:STN:280:DyaK1M7msFarug%3D%3D
17. JD Brandt 2003 Does benzalkonium chloride cause cataract? Arch Ophthalmol 121 892-893 10.1001/archopht.121.6.892 12796264
18. SC Patel GL Spaeth 1995 Compliance in patients prescribed eyedrops for glaucoma Ophthalmic Surg 26 233-236 1:STN:280:ByqA1c%2FhtlY%3D 7651690
19. SJ Coons SL Sheahan SS Martin J Hendricks CA Robbins JA Johnson 1994 Predictors of medication noncompliance in a sample of older adults Clin Ther 16 110-117 1:STN:280:ByuB28ritlE%3D 8205597
20. TJ Zimmerman HE Kaufman 1977 Timolol, dose response and duration of action Arch Ophthalmol 95 605-607 1:CAS:528:DyaE2sXkslymt7w%3D 322649
21. 21. Zimmerman T. Medicinal therapy for glaucoma. In: Eid TM, Spaeth GL (Eds). The glaucomas: Concepts and fundamentals. Lippencott Williams and Wilkins, 2000, pp. 227-245.
22. P Hoyng LM Beek van 2000 Pharmacological therapy for glaucoma: A review Drugs 59 411-434 10.2165/00003495-200059030-00003 1:CAS:528:DC%2BD3cXjtV2hsbc%3D 10776828
23. CD McMahon RN Shaffer HD Hoskins Jr J Hetherington Jr 1979 Adverse effects experienced by patients taking timolol Am J Ophthalmol 88 736-738 1:STN:280:Bi%2BD283mt1Y%3D 507146
24. EM Buskirk Van 1980 Adverse reactions from timolol administration Ophthalmology 87 447-450 7402590
25. FT Fraunfelder 1980 Interim report: National registry of possible drug-induced ocular side effects Ophthalmology 87 87-90 1:STN:280:Bi%2BB3M%2FpvVQ%3D 7383547
26. WL Nelson FT Fraunfelder JM Sills JB Arrowsmith JN Kuritsky 1986 Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985 Am J Ophthalmol 102 606-611 1:STN:280:BiiD2cnitl0%3D 3777080
27. TM Velde FE Kaiser 1983 Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient Arch Intern Med 143 162710.1001/archinte.143.8.1627 1:STN:280:BiyB2Mrlsl0%3D 6870450
28. JD Bartlett M Olivier T Richardson R Whitaker Jr D Pensyl MR Wilson 1999 Central nervous system and plasma lipid profiles associated with carteolol and timolol in postmenopausal black women J Glaucoma 8 388-395 1:STN:280:DC%2BD3c%2FmslOrug%3D%3D 10604299
29. ST Simmons ML Earl 2002 Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: Tolerance and peak intraocular pressure lowering Ophthalmology 109 307-315 10.1016/ S0161-6420(01)00936-8 11825814
30. WC Stewart 1994 Carteolol, an ophthalmic β-adrenergic blocker with intrinsic sympathomimetic activity J Glaucoma 3 339-345
31. RJ Valuck JI Perlman C Anderson GI Wortman 2001 Co-prescribing of medications used to treat obstructive lung disease, congestive heart failure and depression among users of topical beta blockers: Estimates from three US Veterans Affairs Medical Centers Pharmacoepidemiol Drug Saf 10 511-516 10.1002/pds.634 1:STN:280:DC%2BD38%2FpvFWqtQ%3D%3D 11828833
32. JS Schuman 2000 Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2 Ophthalmology 107 1171-1177 1:STN:280:DC%2BD3czhtl2rsA%3D%3D 10857839
33. Quinidine (package insert). Corona, CA: Watson Pharmaceuticals, Inc., 2004.
34. LS Harris SH Greenstein AF Bloom 1986 Respiratory difficulties with betaxolol Am J Ophthalmol 102 274-275 1:STN:280:BimB1Mzhs1w%3D 3740189
35. NN Osborne M Ugarte M Chao 1999 Neuroprotection in relation to retinal ischemia and relevance to glaucoma Surv Ophthalmol 43 S102-S128 10416754
36. Nordmann J, Mertz B, Yannoulis N, Schwenninger C, Kapik B, Shams N, and the Unoprostone Monotherapy Study Group-EU. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data. Am J Ophthalmol 2002; 133: 1-10.
37. Javitt J, Goldberg I, and the Brimonidine Outcomes Study Group II. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. J Glaucoma 2000; 9: 398-408.
38. Serle JB, and the Brimonidine Study Group III. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. Surv Ophthalmol 1996; 41(suppl 1): S39-S47.
39. ME Turacli RG Ozden MA Gurses 1998 The effect of betaxolol on ocular blood flow and visual fields in patients with normotension glaucoma Eur J Ophthalmol 8 62-66 1:STN:280:DyaK1czjvValsg%3D%3D 9673472
40. O Arend A Harris S Arend A Remky BJ Martin 1998 The acute effect of topical beta-adrenoreceptor blocking agents on retinal and optic nerve head circulation Acta Ophthalmol Scand 76 43-49 1:CAS:528:DyaK1cXit1Kgsro%3D 9541433
41. A Harris O Arend HS Chung L Kagemann L Cantor B Martin 2000 A comparative study of betaxolol and dorzolomide effect on ocular circulation in normal-tension glaucoma patients Ophthalmology 107 430-434 1:STN:280:DC%2BD3c7nsFSnsw%3D%3D 10711877
42. Silver LH, and the Brinzolamide Primary Therapy Study Group. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 1998; 126: 400-408.
43. L Wayman LI Larsson T Maus A Alm R Brubaker 1997 Comparison of dorzolamide and timolol as suppressors of aqueous humor flow in humans Arch Ophthalmol 115 1368-1671 1:CAS:528:DyaK2sXns1ygsL0%3D 9366665
44. E Strahlman R Tipping R Vogel the International Dorzolamide Study Group 1995 A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol Arch Ophthalmol 113 1009-1016 1:CAS:528:DyaK2MXnsFGhur0%3D 7639651
45. CM Clineschmidt RD Williams E Snyder IH Adamsons the Dorzolamide-Timolol Combination Study Group 1998 A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide Ophthalmology 105 1952-1959 10.1016/S0161-6420(98)91047-8 1:STN:280:DyaK1M%2FgtlKgtQ%3D%3D 9787369
46. A Martinez F Gonzalez C Capeans R Perez M Sanchez-Salorio 1999 Dorzolamide effect on ocular blood flow Invest Ophthalmol Vis Sci 40 1270-1275 1:STN:280:DyaK1M3kvFKnsQ%3D%3D 10235564
47. A Harris O Arend S Arend B Martin 1996 Effects of topical dorzolamide on retinal and retrobulbar hemodynamics Acta Ophthalmol Scand 74 569-572 1:CAS:528:DyaK2sXotlajuw%3D%3D 9017044
48. Cosopt® (package insert). Whitehouse Station, NJ: Merck & Co., Inc., 2000.
49. K Strohmaier E Snyder H DuBiner I Adamsons the Dorzolamide-Timolol Study Group 1998 The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components Ophthalmology 105 1936-1944 10.1016/S0161-6420(98)91045-4 1:STN:280:DyaK1M%2FgtlKgtw%3D%3D 9787367
50. J Hutzelmann S Owens A Shedden I Adamsons E Vargas 1998 Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: A clinical equivalence study Br J Ophthalmol 82 1249-1253 1:STN:280:DyaK1M7itlCjsA%3D%3D 9924327
51. CB Toris CB Camras ME Yablonski 1993 Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes Ophthalmology 100 1297-1304 1:STN:280:ByyA1c3ntVM%3D 8371915
52. Simmons ST, for the Alphagan/Trusopt Study Group. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension. Clin Ther 2001; 23: 604-619.
53. Katz LJ, and the Brimonidine Study Group. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients, Am J Ophthalmol 1999; 127: 20-26.
54. LJ Katz 2002 Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension J Glaucoma 11 119-126 11912359
55. NA Zabriskie IK Ahmed LB Cantor 2000 Safety and efficacy of combination therapy with brimonidine 0.2% and latanoprost 0.005% versus fixed timolol 0.5%/dorzolamide 2% in patients with glaucoma or ocular hypertension Invest Ophthalmol Vis Sci 41 suppl 4 S833
56. Lee DA, Gornbein J, Abrams C, and the Glaucoma Trial Study Group. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: A post hoc analysis of an open-label community trial. J Ocul Pharmacol Ther 2000; 16: 3-18.
57. LA Wheeler DW Gil E WoldeMussie 2001 Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma Surv Ophthalmol 45 suppl 3 S290-S294 11377451
58. E WoldeMussie G Ruiz M Wijono LA Wheeler 2001 Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension Ophthalmol Vis Sci 42 2849-2855 1:STN:280:DC%2BD3MnjvFSltQ%3D%3D
59. WoldeMussie E, Craft DK, Wheeler LA. Neuroprotective Effect of Different Formulations of Topically applied Brimonidine after Calibrated Optic Nerve Injury. AGS Poster 2002.
60. E Yoles L Wheeler M Schwartz 1999 Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration Invest Ophthalmol Vis Sci 40 65-73 1:STN:280:DyaK1M7gtlGjsQ%3D%3D 9888428
61. AR Kent JD Nussdorf R David F Tyson D Small D Fellows 2001 Vitreous concentration of topically applied brimonidine tartrate 0.2% Ophthalmology 108 784-787 10.1016/S0161-6420(00)00654-0 1:STN:280:DC%2BD3M3gvVOlug%3D%3D 11297498
62. MP Lafuente MP Villegas-Perez S Mayor ME Aguilera J Mirallesde Imperial M Vidal-Sanz 2002 Neuroprotective effects of brimonidine against transient ischemia-induced retinal ganglion cell death: A dose response in vivo study Exp Eye Res 74 181-189 10.1006/exer.2001.1122 1:CAS:528:DC%2BD38XktVGiur4%3D 11950228
63. Cruz MM, Waker SOrnelas, Kolostyak KP, Ross-Cisneros FN, Sebag J, Hsia CJC, Sadun AA. Influence of Brimonidine (alpha-2 agonist) and Nitroxide Ester (ETOPS) on Retinal Cell Survival Following Apoptotoic Stimulus. AGS Poster 2002
64. Villegas-Perez M, Aviles-Trigueros M, Lafuente MP, et al. Axonal transport preservation in adult rat retinal ganglion cells protected from lschemia induced cell death by brimonidine. AGS Poster 2002.
65. A Alm J Villumsen P Tornquist 1993 Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study Ophthalmology 100 1312-1316 1:STN:280:ByyA1c3ntV0%3D 8371917
66. 2α isopropyl ester analogues for glaucoma treatment Jpn J Ophthalmol 37 259-269 1:CAS:528:DyaK2cXkt1Krsrg%3D 8295363
67. Camras CB, Alm A, Watson P, Stjernschantz J, and the Latanoprost Study Group. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Ophthalmology 1996; 103: 1916-1924.
68. Watson P, Stjernschantz J, and the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension, Ophthalmology 1996; 103: 126-137.
69. HK Mishima K Masuda Y Kitazawa I Azuma M Araie 1996 A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study Ophthalmol 114 929-932 1:CAS:528:DyaK28XltFOitr0%3D
70. TR Walters AM Shapiro MJ Chapin 2000 A comparison of the efficacy, safety, and quality of life of brimonidine with latanoprost vs. latanoprost and timolol Invest Ophthalmol Vis Sci 41 suppl 4 S514
71. WJ Scherer 2002 A retrospective review of non-responders to latanoprost J Ocul Pharmacol Ther 18 287-291 10.1089/108076802760116205 1:CAS:528:DC%2BD38XltVyjt78%3D 12099549
72. Noecker RJ, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM, and the Bimatoprost/Latanoprost Study Group. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003; 135: 55-63.
73. Parrish RK, Palmberg P, Sheu WP and the XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003; 135: 688-703.
74. Camras CB, and the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month masked, multicenter trial in the United States. Ophthalmology 1996; 103: 138-147.
75. MA Johnstone 1997 Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost Am J Ophthalmol 124 544-547 1:STN:280:ByiH28rjtlM%3D 9323945
76. RD Fechtner AS Khouri TJ Zimmerman 1998 Anterior uveitis associated with latanoprost Am J Ophthalmol 126 37-41 10.1016/S0002-9394(98)00071-3 1:STN:280:DyaK1czks1KktQ%3D%3D 9683147
77. RE Warwar JD Bullock D Ballal 1998 Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients Ophthalmology 105 263-268 1:STN:280:DyaK1c7jvFyhsQ%3D%3D 9479285
78. A Alm I Widengard D Kjellgren 1995 Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol Br J Ophthalmol 79 12-16 1:STN:280:ByqC1cnktl0%3D 7880782
79. J Morales ZM Shihab SM Brown MR Hodges 2001 Herpes simplex virus dermatitis in patients using latanoprost Am J Ophthalmol 132 114-116 10.1016/S0002-9394(01)01012-1 1:STN:280:DC%2BD3MzosVWksQ%3D%3D 11438068
80. M Wand CM Gilbert TJ Liesegang 1999 Latanoprost and herpes simplex keratitis Am J Ophthalmol 127 602-604 10.1016/S0002-9394(99)00050-1 1:STN:280:DyaK1M3msFGhtw%3D%3D 10334356
81. Y Goh J Kishino 1994 Pharmacological characterization of prostaglandin-related ocular hypotensive agents Jpn J Ophthalmol 38 236-245 1:CAS:528:DyaK2MXitFGisLo%3D
82. T Taniguchi MS Haque K Sugiyama N Hori Y Kitazawa 1996 Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbits J Ocul Pharmacol Ther 12 489-498 1:CAS:528:DyaK28Xns1ShtLY%3D 8951685
83. M Sakurai M Araie T Oshika M Mori N Shoji K Masuda 1993 Effects of topical application of UF-021, a novel prostaglandin-related compound, on aqueous humor dynamics in rabbit Jpn J Ophthalmol 37 252-258 1:CAS:528:DyaK2cXitlKqs7g%3D 8295362
84. I Azuma K Masuda Y Kitazawa M Takase H Yamamura 1993 Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension Jpn J Ophthalmol 37 514-525 1:STN:280:ByuC1MvmvFE%3D 8145398
85. T Yamamoto Y Kitazawa I Azuma K Masuda 1997 Clinical evaluation of UF-021 (Rescula; isopropyl unoprostone) Surv Ophthalmol 41 suppl 2 S99-S103 9154284
86. E Polska A Doelemeyer A Luksch 2002 Partial antagonism of endothelin 1-induced vasoconstriction in the human choroid by topical unoprostone isopropyl Arch Ophthalmol 120 348-352 1:CAS:528:DC%2BD38Xitlyqtb0%3D 11879139
87. Netland PA, Landry T, Sullivan EK, et al., and the Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hyperténsion. Am J Ophthalmol 2001; 132: 472-484.
88. Orengo-Nania S, Landry T, Von Tress M, Silver LH, Weiner A, Davis AA, and the Travoprost Study Group. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Am J Ophthalmol 2001; 132: 860-868.
89. Sherwood M, Brandt J, for the Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 2001; 45(suppl 4): S361-368.
90. Brandt JD, VanDenburgh AM, Chen K, Whitcup SM, and the Bimatoprost Study Group. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: A 3-month clinical trial. Ophthalmology 2001; 108: 1023-1031.
91. Gandolfi S, Simmons ST, Sturm R, Chen K, VanDenburgh AM, and the Bimatoprost Study Group 3. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001; 18: 110-121.
92. Higginbotham EJ, Schuman JS, Goldberg I, et al., and the Bimatoprost Study Group 1 and 2. One-year randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 2002; 120: 1286-1293.
93. M Wand AR Gaudio 2002 Cystoid macular edema associated with ocular hypotensive lipids Am J Ophthalmol 133 403-405 11860980
94. DM Kroll JS Schuman 2002 Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma Am J Ophthalmol 133 401-403 10.1016/S0002-9394(01)01360-5 11860979